MX384382B - Composiciones anticancerígenas. - Google Patents
Composiciones anticancerígenas.Info
- Publication number
- MX384382B MX384382B MX2017007201A MX2017007201A MX384382B MX 384382 B MX384382 B MX 384382B MX 2017007201 A MX2017007201 A MX 2017007201A MX 2017007201 A MX2017007201 A MX 2017007201A MX 384382 B MX384382 B MX 384382B
- Authority
- MX
- Mexico
- Prior art keywords
- arn
- prostate cancer
- meth
- poly
- acrylate copolymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 | ||
| PCT/US2015/063667 WO2016090101A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007201A MX2017007201A (es) | 2018-01-30 |
| MX384382B true MX384382B (es) | 2025-03-14 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007201A MX384382B (es) | 2014-12-05 | 2015-12-03 | Composiciones anticancerígenas. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20170360707A1 (enExample) |
| EP (2) | EP3226842B1 (enExample) |
| JP (1) | JP6767368B2 (enExample) |
| KR (1) | KR102348325B1 (enExample) |
| CN (2) | CN106999430A (enExample) |
| AR (1) | AR102924A1 (enExample) |
| AU (1) | AU2015358493B2 (enExample) |
| CA (1) | CA2969661C (enExample) |
| CL (1) | CL2017001372A1 (enExample) |
| CO (1) | CO2017005573A2 (enExample) |
| CR (1) | CR20170217A (enExample) |
| CY (1) | CY1123856T1 (enExample) |
| DK (1) | DK3226842T3 (enExample) |
| EA (1) | EA035988B1 (enExample) |
| ES (2) | ES3021508T3 (enExample) |
| HR (1) | HRP20201902T1 (enExample) |
| HU (1) | HUE051888T2 (enExample) |
| IL (1) | IL252324B (enExample) |
| LT (1) | LT3226842T (enExample) |
| MA (2) | MA55404A (enExample) |
| MD (1) | MD3226842T2 (enExample) |
| MX (1) | MX384382B (enExample) |
| NI (1) | NI201700069A (enExample) |
| PL (1) | PL3226842T3 (enExample) |
| PT (1) | PT3226842T (enExample) |
| RS (1) | RS61466B1 (enExample) |
| SG (1) | SG11201704264UA (enExample) |
| SI (1) | SI3226842T1 (enExample) |
| TW (1) | TWI683662B (enExample) |
| UA (1) | UA121123C2 (enExample) |
| WO (1) | WO2016090101A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| RS62421B1 (sr) | 2014-12-05 | 2021-10-29 | Aragon Pharmaceuticals Inc | Anti-kancerogeni sastavi |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| EP3773509B1 (en) * | 2018-04-06 | 2023-11-01 | Capsugel Belgium NV | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
| WO2020144649A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising enzalutamide dispersed in apple sauce |
| KR20210122275A (ko) | 2019-01-30 | 2021-10-08 | 얀센 파마슈티카 엔.브이. | 분자 아형에 기초하여 전립선암을 치료하는 방법 |
| SG11202107712SA (en) | 2019-01-30 | 2021-08-30 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| DK4054572T3 (da) | 2019-11-04 | 2026-08-03 | Aragon Pharmaceuticals Inc | Apalutanid til behandling af ikke-metastatisk kastrationsresistent prostatacancer hos subjekter med svært nedsat leverfunktion |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| JP2026515598A (ja) | 2023-03-16 | 2026-05-19 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト | ホルモン感受性前立腺がんの生化学的再発を有する患者の処置のためのアンドロゲン受容体アンタゴニスト |
| WO2026052846A1 (en) | 2024-09-09 | 2026-03-12 | Synthon B.V. | Pharmaceutical formulation comprising apalutamide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20032647A3 (cs) | 2001-04-02 | 2004-09-15 | Astrazeneca Ab | Pevná farmaceutická kompozice obsahující 4-kyanotrifluor-3-(4-fluorfenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidin a PVP |
| JPWO2003077827A1 (ja) * | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | 医薬固体分散体の製造方法 |
| JP2007518670A (ja) * | 2003-12-15 | 2007-07-12 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | 苦味のある薬物、及びｐＨ感受性ポリマーを含む風味マスクされた医薬組成物 |
| BRPI0709771B1 (pt) * | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| EP3124481B1 (en) * | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| CA2839301C (en) * | 2011-06-15 | 2021-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| UA123142C2 (uk) | 2012-06-07 | 2021-02-24 | Арагон Фармасьютікалз, Інк. | Кристалічні форми модулятора андрогенного рецептора |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| TWI673051B (zh) * | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物 |
| WO2014052237A1 (en) * | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (en) * | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| NZ708272A (en) * | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| KR20160058774A (ko) * | 2013-08-12 | 2016-05-25 | 토카이 파마슈티컬, 아이엔씨. | 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커 |
| CN106102716A (zh) * | 2014-02-05 | 2016-11-09 | 斯洛文尼亚莱柯制药股份有限公司 | 雄激素受体拮抗剂的固体药物组合物 |
-
2015
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en not_active Ceased
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro not_active IP Right Cessation
- 2015-12-03 ES ES20209559T patent/ES3021508T3/es active Active
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active Active
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 MX MX2017007201A patent/MX384382B/es unknown
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 EP EP20209559.2A patent/EP3842034B1/en active Active
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh not_active IP Right Cessation
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 HR HRP20201902TT patent/HRP20201902T1/hr unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 CN CN202211487545.0A patent/CN115837010B/zh active Active
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500979A1 (en) | Anticancer compositions | |
| MX387933B (es) | Composiciones anticancerigenas. | |
| EA201791252A1 (ru) | Противораковые композиции | |
| JOP20200097A1 (ar) | معدل مستقبل أندروجين واستخداماته | |
| PH12018502334A1 (en) | Anticancer compositions | |
| AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| TH170798A (th) | องค์ประกอบต้านมะเร็ง |